ERGIC2

Summary

ERGIC2 (ERGIC and golgi 2, HGNC:30208) is a protein-coding gene on chromosome 12p11.22, encoding Endoplasmic reticulum-Golgi intermediate compartment protein 2 (Q96RQ1). Possible role in transport between endoplasmic reticulum and Golgi.

ERGIC2, or PTX1, is a ubiquitously expressed nuclear protein that is downregulated in prostate carcinoma (Kwok et al., 2001 [PubMed 11445006]).

Source: NCBI Gene 51290 — RefSeq curated summary.

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 69 total — 1 pathogenic
• MANE Select transcript: NM_016570

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30208
Approved symbol	ERGIC2
Name	ERGIC and golgi 2
Location	12p11.22
Locus type	gene with protein product
Status	Approved
Aliases	PTX1, Erv41
Ensembl gene	ENSG00000087502
Ensembl biotype	protein_coding
OMIM	612236
Entrez	51290

Gene structure

Transcript identifiers

Ensembl transcripts: 23 — 20 protein_coding, 2 nonsense_mediated_decay, 1 retained_intron

ENST00000360150, ENST00000546509, ENST00000546839, ENST00000548098, ENST00000548441, ENST00000548909, ENST00000549182, ENST00000550353, ENST00000551467, ENST00000552132, ENST00000552155, ENST00000869902, ENST00000869903, ENST00000869904, ENST00000869905, ENST00000869906, ENST00000869907, ENST00000869908, ENST00000869909, ENST00000869910, ENST00000869911, ENST00000966762, ENST00000966763

RefSeq mRNA: 1 — MANE Select: NM_016570 NM_016570

CCDS: CCDS41765

Canonical transcript exons

ENST00000360150 — 14 exons

Exon	Start	End
ENSE00000557344	29350013	29350068
ENSE00000557345	29349079	29349177
ENSE00000734382	29361645	29361685
ENSE00000734384	29366877	29366947
ENSE00000734385	29368241	29368287
ENSE00000835977	29343120	29343282
ENSE00001273303	29345443	29345540
ENSE00001273326	29357623	29357724
ENSE00001342532	29371528	29371670
ENSE00002377131	29381115	29381172
ENSE00002426265	29337352	29341218
ENSE00003632947	29341734	29341816
ENSE00003785317	29370114	29370222
ENSE00003789004	29356382	29356477

Expression profiles

Bgee: expression breadth ubiquitous, 285 present calls, max score 97.53.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 34.9618 / max 842.0722, expressed in 1794 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
130308	34.0789	1794
130309	0.8829	573

Top tissues by expression

288 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
buccal mucosa cell	CL:0002336	97.53	gold quality
calcaneal tendon	UBERON:0003701	97.12	gold quality
colonic epithelium	UBERON:0000397	96.57	gold quality
adrenal tissue	UBERON:0018303	96.54	gold quality
islet of Langerhans	UBERON:0000006	96.42	gold quality
germinal epithelium of ovary	UBERON:0001304	96.24	gold quality
stromal cell of endometrium	CL:0002255	96.08	gold quality
gingival epithelium	UBERON:0001949	96.08	gold quality
superficial temporal artery	UBERON:0001614	96.07	gold quality
oocyte	CL:0000023	95.99	gold quality
ventricular zone	UBERON:0003053	95.71	gold quality
tonsil	UBERON:0002372	95.48	gold quality
mucosa of paranasal sinus	UBERON:0005030	95.48	gold quality
decidua	UBERON:0002450	95.39	gold quality
palpebral conjunctiva	UBERON:0001812	95.18	gold quality
tibia	UBERON:0000979	95.07	gold quality
cauda epididymis	UBERON:0004360	94.96	gold quality
superior surface of tongue	UBERON:0007371	94.95	gold quality
corpus epididymis	UBERON:0004359	94.89	gold quality
corpus callosum	UBERON:0002336	94.83	gold quality
rectum	UBERON:0001052	94.77	gold quality
mammary duct	UBERON:0001765	94.62	gold quality
gall bladder	UBERON:0002110	94.56	gold quality
ganglionic eminence	UBERON:0004023	94.49	gold quality
endometrium	UBERON:0001295	94.45	gold quality
body of pancreas	UBERON:0001150	94.38	gold quality
secondary oocyte	CL:0000655	94.29	gold quality
seminal vesicle	UBERON:0000998	94.19	gold quality
amniotic fluid	UBERON:0000173	94.18	gold quality
trigeminal ganglion	UBERON:0001675	94.18	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	21.22
E-GEOD-81383	no	616.89

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

58 targeting ERGIC2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-32-5P	99.98	75.21	1964
HSA-MIR-92A-3P	99.98	75.21	1960
HSA-MIR-92B-3P	99.98	75.25	1955
HSA-MIR-25-3P	99.98	74.60	1817
HSA-MIR-363-3P	99.98	74.72	1821
HSA-MIR-367-3P	99.98	74.83	1819
HSA-MIR-3617-3P	99.98	67.86	918
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-507	99.97	70.11	1915
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-557	99.96	70.01	1640
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-548AE-3P	99.93	72.66	4867
HSA-MIR-548AH-3P	99.93	72.54	4872
HSA-MIR-548AM-3P	99.93	72.54	4872
HSA-MIR-548AQ-3P	99.93	72.66	4867
HSA-MIR-4778-3P	99.93	70.40	1818
HSA-MIR-205-3P	99.92	69.92	3165
HSA-MIR-627-3P	99.90	71.42	3316
HSA-MIR-548D-3P	99.87	70.67	4362
HSA-MIR-30A-3P	99.87	69.74	2928
HSA-MIR-30D-3P	99.87	69.92	2917
HSA-MIR-30E-3P	99.87	69.68	2942
HSA-MIR-548BB-3P	99.86	70.58	4354

Literature-anchored findings (GeneRIF, showing 5)

• may play an important role in the growth and tumorigenicity of PC-3 prostate tumor cells (PMID:12932305)
• ERGIC-32 functions as a modulator of the hErv41-hErv46 complex by stabilizing hErv46 (PMID:15308636)
• Ectopic expression of a partial sequence of PTX1 (Met84 - Leu225) as a VP22-fusion protein in prostate cancer cell line, PC-3, induced cellular senescence. (PMID:16989575)
• CDA14 participated in the elongation factor 1alpha regulated mechanisms (PMID:17980171)
• A variant of ERGIC2 with four coding bases deleted has an abrogated function as a transport shuttle, but does continue to upregulate the heme oxygenase 1 gene, suggesting that it may be involved in the oxidative stress pathway. (PMID:24303950)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	ERGIC2	ENSDARG00000020224
danio_rerio	ergic2	ENSDARG00000051936
mus_musculus	Ergic2	ENSMUSG00000030304
rattus_norvegicus	Ergic2	ENSRNOG00000001852
drosophila_melanogaster	CG4293	FBGN0024983
caenorhabditis_elegans		WBGENE00007668

Paralogs (2): ERGIC1 (ENSG00000113719), ERGIC3 (ENSG00000125991)

Protein

Protein identifiers

Endoplasmic reticulum-Golgi intermediate compartment protein 2 — Q96RQ1 (reviewed: Q96RQ1)

All UniProt accessions (10): Q96RQ1, F8VPA6, F8VR88, F8VRW9, F8VUZ2, F8W0R1, H0YHJ8, H0YHS0, H0YI50, H0YI58

UniProt curated annotations — full annotation on UniProt →

Function. Possible role in transport between endoplasmic reticulum and Golgi.

Subunit / interactions. May form a heteromeric complex composed of ERGIC1, ERGIC2 and ERGIC3. Interacts with ERGIC3, the interaction is required for the stable expression of both proteins. May interact with EEF1A1.

Subcellular location. Endoplasmic reticulum-Golgi intermediate compartment membrane. Golgi apparatus. cis-Golgi network membrane. Endoplasmic reticulum membrane. Cytoplasm. Nucleus.

Tissue specificity. Ubiquitously expressed.

Similarity. Belongs to the ERGIC family.

RefSeq proteins (1): NP_057654* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR012936	Erv_C	Domain
IPR039542	Erv_N	Domain
IPR045888	Erv	Family

Pfam: PF07970, PF13850

UniProt features (9 total): topological domain 3, sequence conflict 3, transmembrane region 2, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96RQ1-F1	81.21	0.39

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 163 (showing top): GSE45365_HEALTHY_VS_MCMV_INFECTION_CD8_TCELL_IFNAR_KO_UP, TAATAAT_MIR126, GAUSSMANN_MLL_AF4_FUSION_TARGETS_C_UP, IVANOVA_HEMATOPOIESIS_MATURE_CELL, GOBP_VESICLE_MEDIATED_TRANSPORT, chr12p11, WEI_MYCN_TARGETS_WITH_E_BOX, GOBP_ENDOPLASMIC_RETICULUM_TO_GOLGI_VESICLE_MEDIATED_TRANSPORT, MILI_PSEUDOPODIA_HAPTOTAXIS_UP, GOCC_COATED_VESICLE, CUI_TCF21_TARGETS_2_DN, ACEVEDO_LIVER_CANCER_UP, NUYTTEN_EZH2_TARGETS_DN, GOCC_TRANSPORTER_COMPLEX, GOCC_NUCLEAR_OUTER_MEMBRANE_ENDOPLASMIC_RETICULUM_MEMBRANE_NETWORK

GO Biological Process (3): endoplasmic reticulum to Golgi vesicle-mediated transport (GO:0006888), retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum (GO:0006890), vesicle-mediated transport (GO:0016192)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (12): nucleus (GO:0005634), nucleolus (GO:0005730), cytoplasm (GO:0005737), endoplasmic reticulum (GO:0005783), endoplasmic reticulum membrane (GO:0005789), Golgi apparatus (GO:0005794), membrane (GO:0016020), COPII-coated ER to Golgi transport vesicle (GO:0030134), endoplasmic reticulum-Golgi intermediate compartment membrane (GO:0033116), retrograde cargo receptor complex, Golgi to ER (GO:0061852), transporter complex (GO:1990351), Golgi membrane (GO:0000139)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cytoplasm	3
intracellular membrane-bounded organelle	3
Golgi vesicle transport	2
cellular anatomical structure	2
endomembrane system	2
bounding membrane of organelle	2
intercellular transport	1
intracellular transport	1
transport	1
cellular process	1
binding	1
nuclear lumen	1
intracellular membraneless organelle	1
intracellular anatomical structure	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1
coated vesicle	1
endoplasmic reticulum-Golgi intermediate compartment	1
cargo receptor complex	1
protein-containing complex	1
Golgi apparatus	1

Protein interactions and networks

STRING

2180 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ERGIC2	ERGIC3	Q9Y282	941
ERGIC2	UBN1	Q9NPG3	846
ERGIC2	RNF215	Q9Y6U7	595
ERGIC2	TMPRSS12	Q86WS5	571
ERGIC2	RER1	O15258	544
ERGIC2	CCDC61	Q9Y6R9	531
ERGIC2	BET1	O15155	527
ERGIC2	SURF4	O15260	506
ERGIC2	LMAN1	P49257	480
ERGIC2	ZNF10	P21506	473
ERGIC2	SEC13	P55735	470
ERGIC2	STX5	Q13190	461
ERGIC2	RAB8B	Q92930	448
ERGIC2	ZNF382	Q96SR6	442
ERGIC2	KDELR1	P24390	420

IntAct

116 interactions, top by confidence:

A	B	Type	Score
SIL1	HSPA5	psi-mi:“MI:0914”(association)	0.740
COPG1	COPB2	psi-mi:“MI:0914”(association)	0.730
PPP2R5A	PPP2R1B	psi-mi:“MI:0914”(association)	0.670
COPG1	COPE	psi-mi:“MI:0914”(association)	0.640
HSD17B2	ERGIC2	psi-mi:“MI:0915”(physical association)	0.640
ZFPL1	PPP2R5E	psi-mi:“MI:0914”(association)	0.640
ERGIC2	ERGIC3	psi-mi:“MI:0915”(physical association)	0.560
ERGIC3	ERGIC2	psi-mi:“MI:0915”(physical association)	0.560
ERGIC2		psi-mi:“MI:0915”(physical association)	0.550
LPAR1	TMEM223	psi-mi:“MI:0914”(association)	0.530
SPPL2B	UQCRQ	psi-mi:“MI:0914”(association)	0.530
ENPP7	TUBB3	psi-mi:“MI:0914”(association)	0.530
TM2D2	TMEM97	psi-mi:“MI:0914”(association)	0.530
YIPF3	TMEM120B	psi-mi:“MI:0914”(association)	0.530
PPP2R5A	AXIN1	psi-mi:“MI:0914”(association)	0.530
CHRND	TPST2	psi-mi:“MI:0914”(association)	0.530
SLC22A15	ZFPL1	psi-mi:“MI:0914”(association)	0.530
VAMP5	NBAS	psi-mi:“MI:0914”(association)	0.530
DLK1	SCAMP3	psi-mi:“MI:0914”(association)	0.530
CRHBP	TNIP1	psi-mi:“MI:0914”(association)	0.530
GHITM	MFN2	psi-mi:“MI:0914”(association)	0.530
env	PGRMC1	psi-mi:“MI:0914”(association)	0.460
ERGIC2	MAGT1	psi-mi:“MI:0915”(physical association)	0.400
HSCB	RBP5	psi-mi:“MI:0914”(association)	0.350
YIPF3	TMEM223	psi-mi:“MI:0914”(association)	0.350

BioGRID (289): ERGIC2 (Affinity Capture-MS), ERGIC2 (Affinity Capture-MS), ERGIC2 (Affinity Capture-MS), ERGIC2 (Affinity Capture-MS), ERGIC2 (Affinity Capture-MS), ERGIC2 (Affinity Capture-MS), ERGIC2 (Proximity Label-MS), ERGIC2 (Affinity Capture-MS), ERGIC2 (Affinity Capture-MS), ERGIC2 (Affinity Capture-MS), ERGIC2 (Affinity Capture-MS), ERGIC2 (Affinity Capture-MS), ERGIC2 (Affinity Capture-MS), ERGIC2 (Affinity Capture-MS), ERGIC2 (Affinity Capture-MS)

ESM2 similar proteins: A5A6J8, A5D7U4, O18824, O35114, O35409, P05026, P05027, P05028, P06583, P07340, P08251, P13638, P14094, P14231, P14415, P16671, P26201, P27615, P51168, P58421, P70110, P70627, P97943, Q07969, Q08857, Q14108, Q28030, Q2HZ96, Q4R4V5, Q4R5C3, Q5F362, Q5J583, Q5R8S8, Q60417, Q61009, Q6P9A2, Q708S3, Q708S7, Q7T2D4, Q8L8W0

Diamond homologs: P39727, Q09895, Q4R5C3, Q4R8X1, Q54DW2, Q5EAE0, Q5R8G3, Q66KH2, Q6NS19, Q6NVS2, Q7T2D4, Q803I2, Q96RQ1, Q9CQE7, Q9CR89, Q9Y282, O94283

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 161 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Lysosphingolipid and LPA receptors	5	33.7×	9e-06
Signaling by GSK3beta mutants	5	33.7×	9e-06
CTNNB1 S33 mutants aren’t phosphorylated	5	33.7×	9e-06
CTNNB1 S37 mutants aren’t phosphorylated	5	33.7×	9e-06
CTNNB1 S45 mutants aren’t phosphorylated	5	33.7×	9e-06
CTNNB1 T41 mutants aren’t phosphorylated	5	33.7×	9e-06
Beta-catenin phosphorylation cascade	5	29.7×	2e-05
Signaling by WNT in cancer	5	26.6×	3e-05

Disease & clinical

Clinical variants and AI predictions

ClinVar

69 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	47
Likely benign	2
Benign	1

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
4796686	NM_016570.3(ERGIC2):c.572+5G>A	Pathogenic

SpliceAI

1886 predictions. Top by Δscore:

Variant	Effect	Δscore
12:29345441:AC:A	donor_gain	1.0000
12:29345442:CC:C	donor_gain	1.0000
12:29349070:AATAC:A	donor_loss	1.0000
12:29349071:ATAC:A	donor_loss	1.0000
12:29349072:TACTT:T	donor_loss	1.0000
12:29349073:AC:A	donor_loss	1.0000
12:29349074:C:A	donor_loss	1.0000
12:29349075:T:TG	donor_loss	1.0000
12:29349076:TA:T	donor_loss	1.0000
12:29349077:A:AC	donor_gain	1.0000
12:29349077:A:AG	donor_loss	1.0000
12:29349077:ACGAT:A	donor_gain	1.0000
12:29349078:C:CT	donor_gain	1.0000
12:29349078:C:T	donor_loss	1.0000
12:29349078:CG:C	donor_gain	1.0000
12:29349078:CGA:C	donor_gain	1.0000
12:29349078:CGAT:C	donor_gain	1.0000
12:29349078:CGATC:C	donor_gain	1.0000
12:29349174:TAAG:T	acceptor_gain	1.0000
12:29349178:C:CC	acceptor_gain	1.0000
12:29350008:CTTA:C	donor_loss	1.0000
12:29350009:TTA:T	donor_loss	1.0000
12:29350010:TA:T	donor_loss	1.0000
12:29350011:A:AC	donor_gain	1.0000
12:29350011:ACA:A	donor_loss	1.0000
12:29350011:ACATT:A	donor_gain	1.0000
12:29350012:C:CT	donor_gain	1.0000
12:29350012:CA:C	donor_gain	1.0000
12:29350012:CAT:C	donor_gain	1.0000
12:29350012:CATT:C	donor_gain	1.0000

AlphaMissense

2500 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:29343236:A:T	I291K	1.000
12:29343239:C:T	G290E	1.000
12:29343240:C:A	G290W	1.000
12:29356398:G:C	H186D	1.000
12:29368258:A:T	V82D	1.000
12:29343197:A:T	V304D	0.999
12:29343232:A:C	F292L	0.999
12:29343232:A:T	F292L	0.999
12:29343234:A:G	F292L	0.999
12:29343236:A:C	I291R	0.999
12:29343240:C:G	G290R	0.999
12:29343240:C:T	G290R	0.999
12:29343278:C:G	R277P	0.999
12:29349145:A:G	S221P	0.999
12:29349163:G:C	H215D	0.999
12:29350038:A:C	H201Q	0.999
12:29350038:A:T	H201Q	0.999
12:29350040:G:C	H201D	0.999
12:29356385:C:A	G190V	0.999
12:29356385:C:T	G190D	0.999
12:29356386:C:G	G190R	0.999
12:29356394:A:C	I187R	0.999
12:29356394:A:T	I187K	0.999
12:29356396:G:C	H186Q	0.999
12:29356396:G:T	H186Q	0.999
12:29356402:A:C	N184K	0.999
12:29356402:A:T	N184K	0.999
12:29356406:C:T	G183E	0.999
12:29356407:C:A	G183W	0.999
12:29356414:T:A	K180N	0.999

dbSNP variants (sampled 300 via entrez): RS1000037745 (12:29341653 G>A), RS1000145425 (12:29356730 G>A), RS1000202987 (12:29374121 T>C), RS1000212584 (12:29379649 T>C), RS1000244337 (12:29361304 T>C), RS1000331513 (12:29375708 A>C,G), RS1000429801 (12:29342110 C>G), RS1000507718 (12:29348776 GCA>G), RS1000522114 (12:29347426 T>C), RS1000649452 (12:29341544 C>T), RS1000706250 (12:29355161 A>G), RS1000787998 (12:29380770 G>C), RS1000807551 (12:29362332 T>C), RS1000837848 (12:29368592 C>T), RS1000963276 (12:29355732 T>C)

Disease associations

OMIM: gene MIM:612236 | disease phenotypes: MIM:607812

GenCC curated gene-disease

Mondo (1): craniolenticulosutural dysplasia (MONDO:0011911)

Orphanet (1): Craniolenticulosutural dysplasia (Orphanet:50814)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST006103_5	Interleukin-6 levels	3.000000e-06
GCST006661_121	Male-pattern baldness	5.000000e-16
GCST009391_1784	Metabolite levels	9.000000e-07
GCST90000025_1032	Appendicular lean mass	2.000000e-16

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0004810	interleukin-6 measurement
EFO:0004468	glucose measurement
EFO:0010477	fructose measurement
EFO:0010481	galactose measurement
EFO:0004980	appendicular lean mass

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
C564332	Craniolenticulosutural Dysplasia (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

30 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	decreases expression, decreases methylation	3
Cyclosporine	increases expression	3
sodium arsenite	increases abundance, increases expression	2
Acetaminophen	decreases expression, increases expression	2
aristolochic acid I	decreases expression	1
bisphenol F	affects cotreatment, decreases methylation	1
dicrotophos	decreases expression	1
bisphenol A	decreases expression	1
trichostatin A	affects expression	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
perfluorooctane sulfonic acid	decreases expression	1
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide	decreases expression	1
jinfukang	decreases expression	1
Zoledronic Acid	decreases expression	1
Fulvestrant	decreases methylation, affects cotreatment	1
Arsenic	increases abundance, increases expression	1
Doxorubicin	decreases expression	1
Formaldehyde	decreases expression	1
Manganese	decreases expression	1
Quercetin	decreases expression	1
Dihydrotestosterone	increases expression	1
Tetrachlorodibenzodioxin	decreases expression	1
Thimerosal	increases expression	1
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression	1
Aflatoxin B1	decreases methylation	1
Aflatoxin M1	decreases expression	1
Cadmium Chloride	decreases expression	1
Copper Sulfate	decreases expression	1
Lactic Acid	decreases expression	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1RG	Abcam HeLa ERGIC2 KO	Cancer cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.